Preclinical work has shown KRAS inhibition can delay cancer onset and extend survival in mice with pancreatic intraepithelial neoplasia lesions.

The US Food and Drug Administration has cleared radiopharmaceutical company Aktis Oncology to begin trials of its B7-H3-targeting miniprotein radioconjugate, the company announced this week. Aktis ...

An exclusive option and license deal AviadoBio struck with Astellas Pharma in 2024 has expired, but Astellas Pharma remains a shareholder in the firm.

Researchers also reported results from a separate trial of a gene therapy the company is developing for PKP2-related arrhythmogenic cardiomyopathy.

An imaging sub-study of the ASO in hypertriglyceridemia patients presented at ACC highlights uncertainty about the drug's impact on cardiac outcomes.

A higher dose of the therapy will now be available in the US after the agency rejected Biogen's first application last year due to quality, formulation, and manufacturing issues.

Researchers are enrolling patients with small cell lung cancer, neuroendocrine tumors, and melanoma and will evaluate responses based on biomarkers.

Data at ACC suggest a PGx and clinical score developed at University of Florida to predict Plavix adverse events may be broadly useful for deescalating P2Y12 inhibitor treatment.

The siRNA drug, sold as Redemplo for familial chylomicronemia syndrome, showed promise in severe hypertriglyceridemia in a study presented at ACC.

At ACC, tonlamarsen reduced angiotensinogen in a trial, but the data raise questions about its duration and how well it can treat hypertension.

The recommendation is based on data from a randomized Phase II/III trial and an open-label extension clinical trial of patients with APDS.